Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Neoplasms × relacorilant × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hypertension 2 Diabetes Mellitus, Type 2 2 Cushing Syndrome 2 ACTH Syndrome, Ectopic 2 Pituitary ACTH Hypersecretion 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Fallopian Tube Neoplasms 1

Interventions

Gemcitabine 73 Fluorouracil 30 Oxaliplatin 20 Leucovorin 20 130-nm albumin-bound paclitaxel 16 Capecitabine 14 Irinotecan 11 Albumin-Bound Paclitaxel 10 irinotecan sucrosofate 8 Radiotherapy 6 Taxes 5 Erlotinib Hydrochloride 5 folfirinox 4 rubitecan 3 Surgical Procedures, Operative 3 Specimen Handling 3 Pancreaticojejunostomy 3 Neoadjuvant Therapy 3 Drug Therapy 3 Cisplatin 3 Chemotherapy, Adjuvant 3 ruxolitinib 2 masitinib 2 dehydroftorafur 2 Saline Solution 2 S 1 (combination) 2 Paclitaxel 2 GV1001 peptide 2 Fentanyl 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04329949 2023-11-18

RELIANT

Corcept Therapeutics

Phase 3 Terminated

43 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡